← Leaderboards
Robert H Miller
George Washington University
$14,046,916
Attributed
$19,604,398
Total exposure
17
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.5M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$19,604,398 · 17
By mechanism
R01$12,944,746 · 5
R37$2,617,768 · 1
R21$2,268,015 · 4
P20$960,548 · 3
R33$778,321 · 1
R13$35,000 · 3
Top collaborators
- Paul Joseph Tesar11 shared
- Hening Lin5 shared
- Edward Seto5 shared
- Yan Yang5 shared
- Robert L Findling4 shared
- R. Brad Jones2 shared
Most similar at George Washington University
Same institution · by research overlap
- Hening Lin$20,683,647
- Edward Seto$14,050,703
- David I Watkins$75,196,434
- Jenna Clements$73,296
Others in their field
Top investigators on “Oligodendroglia”
- Brian J Popko · Northwestern University$17,744,920
- Patrizia Casaccia · Univ Of Med/Dent Nj-R W Johnson Med Sch$16,342,723
- Stacey Lynn Clardy · Utah State Higher Education System--University Of Utah$15,144,108
- Stephen Arthur Back · Oregon Health & Science University$14,340,802
- Li-Huei Tsai · Massachusetts Institute Of Technology$14,042,281
- Vittorio Gallo · Child Health And Human Development$13,953,550
Research focus
OligodendrogliaSpinal CordCellsMyelinationMediatingIn VivoMyelinSignal TransductionMultiple SclerosisAdultNeuronsMolecularIn VitroAxonDemyelinating DiseasesResponseCell TypeAffectOligodendrocyte LineageInsightRegulationOligodendrocyte PrecursorDisabilityNeuraxis
Grant awards (59)
Design and development of HDAC11-specific chemical inhibitors for disease treatments$676,591
R01 · FY2025 · AI
Design and development of HDAC11-specific chemical inhibitors for disease treatments$697,517
R01 · FY2024 · AI
Design and development of HDAC11-specific chemical inhibitors for disease treatments$697,517
R01 · FY2023 · AI
Design and development of HDAC11-specific chemical inhibitors for disease treatments$697,517
R01 · FY2022 · AI
Design and development of HDAC11-specific chemical inhibitors for disease treatments$712,892
R01 · FY2021 · AI
Drug-mediated enhancement of myelination$361,830
R01 · FY2019 · NS
Drug-mediated enhancement of myelination$359,245
R01 · FY2018 · NS
development of oligodendrocytes in the spinal cord$346,719
R01 · FY2018 · NS · contact PI
Drug-mediated enhancement of myelination$374,888
R01 · FY2017 · NS
development of oligodendrocytes in the spinal cord$346,719
R01 · FY2017 · NS · contact PI
Assessing the CNS as a source of HIV rebound, and evaluating strategies for immune-mediated reservoir elimination$235,893
R21 · FY2017 · MH · contact PI
Drug-mediated enhancement of myelination$381,959
R01 · FY2016 · NS
development of oligodendrocytes in the spinal cord$346,719
R01 · FY2016 · NS · contact PI
Assessing the CNS as a source of HIV rebound, and evaluating strategies for immune-mediated reservoir elimination$199,375
R21 · FY2016 · MH
Drug-mediated enhancement of myelination$405,069
R01 · FY2015 · NS
High throughput screening and in vivo testing of drugs to enhance remyelination$396,250
R21 · FY2015 · NS
development of oligodendrocytes in the spinal cord$346,719
R01 · FY2015 · NS · contact PI
Cdk5 regulates oligodendrocyte development, myelination and repair$343,438
R01 · FY2015 · NS
High throughput screening and in vivo testing of drugs to enhance remyelination$396,250
R21 · FY2014 · NS
development of oligodendrocytes in the spinal cord$346,719
R01 · FY2014 · NS · contact PI
Cdk5 regulates oligodendrocyte development, myelination and repair$340,003
R01 · FY2014 · NS
Cdk5 regulates oligodendrocyte development, myelination and repair$331,418
R01 · FY2013 · NS · contact PI
Functional Comparison of Induced Pluripotent Stem Cell-Derived Oligodendrocytes i$386,388
R33 · FY2012 · MH
Cdk5 regulates oligodendrocyte development, myelination and repair$343,438
R01 · FY2012 · NS · contact PI
Development of Oligodendrycytes in the Spinal Cord$331,209
R01 · FY2012 · NS · contact PI
Functional Comparison of Induced Pluripotent Stem Cell-Derived Oligodendrocytes i$391,933
R33 · FY2011 · MH · contact PI
Cdk5 regulates oligodendrocyte development, myelination and repair$343,438
R01 · FY2011 · NS · contact PI
Development of Oligodendrycytes in the Spinal Cord$331,209
R01 · FY2011 · NS · contact PI
Development of Oligodendrycytes in the Spinal Cord$334,590
R01 · FY2010 · NS · contact PI
Functional Comparison of Induced Pluripotent Stem Cell-Derived Oligodendrocytes i$234,536
R21 · FY2010 · MH · contact PI
Development of Oligodendrycytes in the Spinal Cord$337,969
R01 · FY2009 · NS · contact PI
Functional Comparison of Induced Pluripotent Stem Cell-Derived Oligodendrocytes i$231,961
R21 · FY2009 · MH · contact PI
Development of Oligodendrycytes in the Spinal Cord$168,113
R01 · FY2009 · NS · contact PI
Development of Oligodendrycytes in the Spinal Cord$337,969
R01 · FY2008 · NS · contact PI
Chemokine Synergy with PDGF Oligodendrocyte Precursors$402,859
R37 · FY2007 · NS · contact PI
UNM COBRE: CORES$146,820
P20 · FY2007 · RR · contact PI
Chemokine Synergy with PDGF Oligodendrocyte Precursors$414,891
R37 · FY2006 · NS · contact PI
Development of Oligodendrocytes in the Spinal cord$319,352
R01 · FY2006 · NS · contact PI
UNM COBRE: CORES$85,923
P20 · FY2006 · RR · contact PI
2006 Myelin Gordon Conference$10,000
R13 · FY2006 · NS · contact PI
Chemokine Synergy with PDGF Oligodendrocyte Precursors$424,875
R37 · FY2005 · NS
Development of Oligodendrocytes in the Spinal cord$327,038
R01 · FY2005 · NS
UNM COBRE: CORES$288,579
P20 · FY2005 · RR
UNM COBRE: CORES$439,226
P20 · FY2004 · RR
Chemokine Synergy with PDGF Oligodendrocyte Precursors$338,787
R37 · FY2004 · NS
Development of Oligodendrocytes in the Spinal cord$327,038
R01 · FY2004 · NS
Gordon Conference on Myelin$15,000
R13 · FY2004 · NS
15th Biennial Meeting of the ISDN$10,000
R13 · FY2004 · NS
Chemokine Synergy with PDGF Oligodendrocyte Precursors$339,940
R37 · FY2003 · NS
Development of Oligodendrocytes in the Spinal cord$327,038
R01 · FY2003 · NS
Oligodendrocyte Loss Following Early Ischemic Injury$191,250
R21 · FY2003 · NS
Chemokine Synergy with PDGF Oligodendrocyte Precursors$341,049
R37 · FY2002 · NS
Development of Oligodendrocytes in the Spinal cord$319,334
R01 · FY2002 · NS
Oligodendrocyte Loss Following Early Ischemic Injury$191,250
R21 · FY2002 · NS
Chemokine Synergy with PDGF Oligodendrocyte Precursors$355,367
R37 · FY2001 · NS
DEVELOPMENT OF OLIGODENDROCYTES IN THE SPINAL CORD$244,714
R01 · FY2001 · NS
Oligodendrocyte Loss Following Early Ischemic Injury$191,250
R21 · FY2001 · NS
DEVELOPMENT OF OLIGODENDROCYTES IN THE SPINAL CORD$237,585
R01 · FY2000 · NS
CHEMOKINE SYNERGY WITH PDGF--OLIGODENDROCYTE PRECURSORS$201,233
R01 · FY2000 · NS